MBX Biosciences, Inc. (MBX)
49.55
-3.86
(-7.23%)
USD |
NASDAQ |
Nov 20, 16:00
49.60
+0.05
(+0.10%)
After-Hours: 20:00
MBX Biosciences Research and Development Expense (TTM) : 101.27M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 101.27M |
| June 30, 2026 | 88.49M |
| March 31, 2026 | 75.23M |
| December 31, 2025 | 79.16M |
| September 30, 2025 | 74.62M |
| June 30, 2025 | 72.10M |
| Date | Value |
|---|---|
| March 31, 2025 | 68.77M |
| December 31, 2024 | 57.42M |
| September 30, 2024 | 49.92M |
| June 30, 2024 | 42.24M |
| March 31, 2024 | 34.32M |
| December 31, 2023 | 28.53M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Ligand Pharmaceuticals, Inc. | 23.09M |
| Xeris Biopharma Holdings, Inc. | 38.38M |
| ANI Pharmaceuticals, Inc. | 50.60M |
| Corcept Therapeutics, Inc. | 241.72M |
| Veru, Inc. | 11.76M |